Quarterly ResultApr 30, 2026, 08:18 AM
ALNY Q1 Revenue +121% to $1.036B; EPS $1.51; Reiterates 2026 Guidance
AI Summary
Alnylam Pharmaceuticals reported strong first-quarter 2026 financial results, with global net product revenues increasing 121% to $1.036 billion, driven primarily by a 153% rise in total TTR revenues to $910 million. The company achieved GAAP net income of $205.99 million, or $1.51 diluted EPS, a significant improvement from a net loss in Q1 2025. Alnylam reiterated its full-year 2026 financial guidance and highlighted pipeline progress, including accelerated enrollment in the TRITON-CM study and new collaborations for ATTR-CM.
Key Highlights
- Q1 2026 Global Net Product Revenues increased 121% to $1.036 billion.
- Q1 2026 Total TTR Net Product Revenues grew 153% to $910 million.
- Q1 2026 GAAP Net Income was $205.99 million, up from a $18.25 million loss in Q1 2025.
- Q1 2026 GAAP Diluted EPS was $1.51, compared to $(0.14) in Q1 2025.
- Reiterated 2026 Total Net Product Revenue guidance of $4.9 billion to $5.3 billion.
- AMVUTTRA net product revenues rose 187% to $889.9 million in Q1 2026.
- TRITON-CM Phase 3 study enrollment for nucresiran is faster than anticipated, expanding target to 1,750 patients.
- Cash, cash equivalents, and marketable securities totaled $3.0 billion as of March 31, 2026.